Pharvaris is developing oral treatments for hereditary angioedema (HAE), leveraging its bradykinin B2 antagonist franchise.Morgan Stanley set a price target of $41 for PHVS, indicating a potential increase of approximately 39.62%.The company's strong phase 2 results and high probability of phase 3 success have led to a buy rating and a target price of $40.Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE). The company is gaining atten ...